Using the SF-36 measure to compare the health impact of multiple sclerosis and Parkinson's disease with normal population health profiles
Using the SF-36 measure to compare the health impact of multiple sclerosis and Parkinson's disease with normal population health profiles
复制标题
DOI：
10.1136/jnnp.74.6.710
复制
发表时间：
2003-06-01
影响因子：
11
通讯作者：
Thompson, AJ
中科院分区：
文献类型：
--
作者：
Riazi, A;Hobart, JC;Thompson, AJ
目的：通过比较多发性硬化症和帕金森病两种慢性神经系统疾病患者在36项健康状况调查量表(SF-36)上的得分和英国人群的健康状况，来检验两种慢性神经系统疾病的相对影响。方法：对638名代表多发性硬化症和227名帕金森病患者进行研究。健康状况采用SF-36进行测评。在控制了年龄、性别、病程、流动性、社会阶层、种族、教育程度、婚姻状况和就业状况后，比较了8个健康领域的得分。结果：多发性硬化症和帕金森病患者在SF-36测量的所有8个领域的健康状况都显著低于普通人群。多发性硬化症和帕金森氏症的相对影响相似，但多发性硬化症导致身体功能评分较差，心理健康评分较好。在没有辅助的情况下走路的轻度多发性硬化症患者在所有维度上的得分也明显低于普通英国人。结论：这一结果突显了对SF-36健康方面进行进一步研究的必要性。然而，适用于多种疾病的通用措施可能无法解决特定疾病影响的临床重要方面。
Objective: To examine the relative impact of two chronic neurological disorders, multiple sclerosis and Parkinson's disease, by comparing patients' scores on the medical outcomes study 36-item short form health survey (SF-36) with the health profile of the United Kingdom population norms.Methods: 638 people representing the full spectrum of multiple sclerosis and 227 patients with Parkinson's disease were studied. Health status was measured by the SF-36. Scores for the eight health domains were compared after controlling for age, sex, disease duration, mobility, social class, ethnicity, education, marital status, and employment status.Results: People with multiple sclerosis and those with Parkinson's disease had significantly worse health than the general population on all eight domains measured by the SF-36. The relative impact of multiple sclerosis and Parkinson's disease were similar, but multiple sclerosis resulted in poorer scores on physical functioning and better scores in mental health. People with mild multiple sclerosis who walked without an aid also had significantly worse scores in all dimensions than the general UK population.Conclusions: The results highlight the need for further research into aspects of health measured by the SF-36. Nevertheless, generic measures that are applicable across multiple diseases may fail to address clinically important aspects of the impact of specific disorders.